There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Imunon (IMNN – Research Report) and CalciMedica (CALC – Research Report) with bullish sentiments.
Imunon (IMNN)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Imunon today and set a price target of $12.00. The company’s shares closed last Wednesday at $0.90.
According to TipRanks.com, Bodnar is a 5-star analyst with an average return of
Imunon has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See Insiders’ Hot Stocks on TipRanks >>
CalciMedica (CALC)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on CalciMedica today and set a price target of $20.00. The company’s shares closed last Wednesday at $4.49.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
CalciMedica has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMNN:
- Imunon Announces CEO Resignation and Interim Leadership Transition
- IMUNON Announces Leadership Change
- Imunon announces lab confirms immunogenicity, protection with IMNN-101
- Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
- Imunon announces Memorial Sloan Kettering Cancer center enrolling patients
